
For more than 25 years, Corcept has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases.
Our commercial portfolio includes treatments for hypercortisolism and oncology, and the company has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. With advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today.
Corcept is headquartered in Redwood City, California. To learn more, visit www.corcept.com
At Corcept Therapeutics, we’re committed to ensuring that patients who need our therapies can access them — efficiently, reliably, and with the support they deserve. The Associate Director, Field Reimbursement Excellence & Flexible Support, Endocrinology plays a critical role in making that happen. This newly created, unique opportunity combines training excellence with hands-on field execution, ensuring continuity of patient access support while developing the capabilities of the Field Reimbursement Team.
This role is responsible for developing, delivering, and continuously improving training programs that enhance the effectiveness of field-based and home-office teams, and serves as the organization's subject matter expert on market access, field reimbursement activities, patient support services, hub and SP operations, and reimbursement for Korlym, Mifepristone AG, and relacorilant (pending FDA approval).
The Associate Director will design and facilitate onboarding programs, advanced learning curricula, certification programs, workshops, and field coaching initiatives focused on reimbursement, payer strategy, specialty pharmacy, patient support services, government programs, and healthcare system dynamics. This position partners closely with Market Access Leadership, Patient Services, Marketing, Compliance, Legal, Medical Affairs, Sales Training, and Commercial Operations to ensure training content remains accurate, compliant, and aligned with business objectives.
In addition to traditional training responsibilities, this role will function as a Flex/Floating Field Reimbursement Manager, providing interim territory coverage, field coaching, launch support, and direct reimbursement assistance to healthcare providers and patients when business needs require.
Responsibilities:
Training Strategy & Curriculum Development
Facilitation & Delivery
Content Development & Knowledge Management
Cross-Functional Collaboration
Measurement & Analytics
Flex / Floating Field Reimbursement Support
Preferred Skills, Qualifications and Technical Proficiencies:
Preferred Education and Experience:
The pay range that the Company reasonably expects to pay for this position is $172,200 – $227,900; the pay ultimately offered may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.
#LI-Remote
Applicants must be currently authorized to work in the United States on a full-time basis.
For information on how Corcept collects, uses, discloses, protects, and otherwise processes personal information and an explanation of the rights and choices available to you with respect to your personal information, please refer to our Privacy Notice link
Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
Please visit our website at: https://www.corcept.com/
Corcept is an Equal Opportunity Employer
Corcept will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third-party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Corcept.

We’ve been unlocking the potential of cortisol modulation for more than 25 years.
We’re leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.
In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome).
Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation.
What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.